A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00789568
First received: November 10, 2008
Last updated: August 11, 2014
Last verified: August 2014
  Purpose

Sapropterin dihydrochloride (subsequently referred to as sapropterin) (Kuvan®) was approved by the FDA for the treatment of hyperphenylalaninemia in 2007. Preclinical and clinical studies and post-marketing surveillance have not demonstrated any specific cardiovascular concerns with sapropterin (Kuvan®). Nonetheless, nonantiarrhythmic drugs may have the potential to prolong QT interval, leading to potentially fatal ventricular tachycardias, including torsades de pointes. As part of the post-marketing commitment, a thorough QT/QTc study will be conducted according to ICH guidelines.


Condition Intervention Phase
Phenylketonuria
Drug: sapropterin dihydrochloride
Drug: Moxifloxacin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Effects of Sapropterin Dihydrochloride Oral Administration on QTc Intervals in Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by BioMarin Pharmaceutical:

Primary Outcome Measures:
  • To determine if a single supratherapeutic dose of sapropterin or a single therapeutic dose of sapropterin has an effect on cardiac repolarization compared with placebo as a change from baseline measured by the subject specific QT correction formula(QTci) [ Time Frame: Complete study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determine if there is a pharmacodynamic relationship between the duration of the QT/QTc intervals and the plasma concentration of sapropterin [ Time Frame: Complete Study ] [ Designated as safety issue: No ]
  • To obtain additional pharmacokinetic information for oral sapropterin at the proposed therapeutic and supra-therapeutic doses. [ Time Frame: Complete Study ] [ Designated as safety issue: No ]
  • To generate additional safety information [ Time Frame: Complete Study ] [ Designated as safety issue: Yes ]

Enrollment: 56
Study Start Date: October 2008
Study Completion Date: October 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin
A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
Drug: sapropterin dihydrochloride
20 mg/kg and 100 mg/kg
Other Name: Kuvan
Experimental: Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin
A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
Drug: sapropterin dihydrochloride
20 mg/kg and 100 mg/kg
Other Name: Kuvan
Active Comparator: Sapropterin Dihydrochloride placebo and Moxifloxacin
No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
Drug: Moxifloxacin
Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
Placebo Comparator: Sapropterin Dihydrocholide placebo and Moxifloxacin placebo
No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Willing and able to provide written, signed informed consent, after the nature of the study has been explained, and prior to any research-related procedures.
  • Sexually active subjects must be willing to use an acceptable method of contraception (double barrier) while participating in the study from screening onwards and for at least 4 weeks after the last dose of study drug.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Willing and able to comply with all study procedures.
  • Healthy male and female subjects between 18 and 50 years of age, inclusive.
  • Body mass index (BMI) of ≥ 18 to < 30 kg/m2 inclusive.
  • Blood pressure in the range of 90 140 mmHg systolic and 50 90 mmHg diastolic at Screening and Check-in. Blood pressures can be repeated up to three times within 10 minutes of initial assessment while remaining in the supine position.
  • No clinically significant 12-lead ECG abnormalities; and a QTc interval < 450 ms for males and < 470 ms for females and a resting heart rate between 45 90 beats/minute at Screening and Check-in.

Exclusion Criteria:

  • Has known hypersensitivity to sapropterin or its excipients, or moxifloxacin.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  • Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Concurrent disease or condition that would interfere with study participation or safety or any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
  • History of clinically significant cardiac condition, eg, myocardial ischemia (including angina) or infarction, congestive heart failure, left ventricular hypertrophy, or cardiomyopathy.
  • Screening, Check-in, or Baseline ECG shows any of the following:

    • Sinus arrhythmia with unacceptable rate variation as judged by the Investigator.
    • Excessive heart rate variation at rest, in the Investigator's opinion.
    • PR interval > 210 ms.
    • QRS interval > 110 ms.
    • QRS and/or T wave that the Investigator judges to be unfavorable for consistently accurate QT measurements (eg, indistinct QRS onset, low amplitude T wave, inverted or terminally inverted T wave, merged T and U waves, or indistinct T offset, prominent U-wave that affects QT measurement).
  • Neuromuscular artifact that cannot be readily eliminated.
  • Documented history of arrhythmias (eg, ventricular arrhythmias and atrial fibrillation).
  • Clinically significant electrolyte disturbances at Screening or Check-in (eg, hypo or hyperkalemia or hypocalcemia) or any condition that could lead to electrolyte disturbances (eg, eating disorder), in the Investigator's opinion.
  • History of palpitations, seizures, unexplained syncopal episodes, or symptomatic arrhythmias.
  • History of additional risk factors for torsade de pointes (eg, history of near-drowning survival due to loss of consciousness, family history of long QT syndrome, or family history of unexplained early sudden death).
  • Any condition that, in the opinion of the Investigator, may compromise absorption, metabolism, or elimination of moxifloxacin.
  • History of cancer within the last five years, with the exception of adequately treated basal cell carcinoma.
  • Known allergy or intolerance to any compound in the test products or any other closely related compound, such as any member of the quinolone class of antimicrobial agents.
  • Unresolved clinically significant laboratory findings, in the Investigator's opinion.
  • Positive antibody screen for HBsAg, hepatitic C virus (HCV), or human immunodeficiency virus (HIV).
  • Acute illness or febrile event within 72 hours of Check-in.
  • Use of tobacco or nicotine-containing products within the last 30 days or have a positive urine test for cotinine prior to Check-in.
  • History of alcohol or drug abuse (according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition [DSM-IV] criteria) within 12 months prior to Check-in or have a positive urine test for alcohol or substances of abuse at Screening or Check-in.
  • Use of alcoholic beverages, caffeine, and grapefruit-containing products 72 hours prior to dosing and until completion of study.
  • Subjects who have taken:

    • Any prescription medications or over-the-counter medications including herbal products (eg, St. John's Wort, milk thistle), antacids and nonsteroidal anti-inflammatory medication for acute pain for more than 5 days within 30 days (or 5 elimination half-lives, whichever is longer) of commencing study drug dosing, with the exception of hormonal contraceptives (oral, implant, patch or injections), including Depo-Provera®. For drugs with an elimination half-life greater than 10 days, the prohibition of prior use will be extended to 60 days.
    • Any planned concomitant medication while in the study, including antacids that contain calcium, magnesium, or aluminum (eg, Rolaids or Tums), the ulcer medicine sucralfate (Carafate), or vitamin or mineral supplements that contain calcium, iron, or zinc from 48 hours prior to Baseline (Day -1) and until completion of the study.
  • Any psychiatric, behavioral, or neuromuscular condition that may compromise the Investigator's evaluation of drug effect.
  • History of intentional suicidal ideation, suicide attempts, depression requiring treatment, or significant depression in the opinion of the Investigator.
  • Subjects who cannot tolerate a controlled, quiet study environment, including avoidance during specified timepoints of music, TV, movies, games, and activities that may cause excitement, emotional tension, or arousal.
  • Subjects who cannot tolerate the study-specified diet.
  • Subjects who are unwilling to comply with study rules, including attempting to void at specified times (prior to ECG timepoints) or maintain quiet, motionless supine posture during specified timepoints.
  • Rigorous exercise ≤ 72 hours prior to Check-in or subjects who will not agree or be able to refrain from rigorous exercise until completion of study.
  • In the opinion of the Investigator, the presence of any other behavior or condition that increases the risk to individual safety or risk of compromising study objectives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00789568

Locations
United States, North Dakota
PRACS Institute, Ltd.
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Study Director: Don Nwose, MD BioMarin Pharmaceutical
  More Information

No publications provided

Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT00789568     History of Changes
Other Study ID Numbers: QTC-001
Study First Received: November 10, 2008
Last Updated: August 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by BioMarin Pharmaceutical:
Hyperphenylalanemia due to Phenylketonuria

Additional relevant MeSH terms:
Phenylketonurias
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Verapamil
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on September 22, 2014